![](/img/cover-not-exists.png)
Leveraging a Clinical Phase Ib Proof-of-Concept Study for the GPR40 Agonist MK-8666 in Patients With Type 2 Diabetes for Model-Informed Phase II Dose Selection
Krug, AW, Vaddady, P, Railkar, RA, Musser, BJ, Cote, J, Ederveen, AGH, Krefetz, DG, DeNoia, E, Free, AL, Morrow, L, Chakravarthy, MV, Kauh, E, Tatosian, DA, Kothare, PALanguage:
english
Journal:
Clinical and Translational Science
DOI:
10.1111/cts.12479
Date:
July, 2017
File:
PDF, 679 KB
english, 2017